The vasodilator effects of clevidipine on human internal mammary artery

Anesthesia and Analgesia

Volumn 85, Issue 5, 1997, Pages 1000-1004

  Huraux, Catherine ^a   Makita, Tetsuji ^a   Szlam, Fania ^a   Nordlander, Margareta ^b   Levy, Jerrold H ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; CALCIUM ANTAGONIST; CLEVIDIPINE; DIHYDROPYRIDINE DERIVATIVE; GLYCERYL TRINITRATE; UNCLASSIFIED DRUG;

ARTERY SPASM; ARTICLE; BLOOD VESSEL GRAFT; CONTROLLED STUDY; DOSE RESPONSE; GRAFT OCCLUSION; HUMAN; HUMAN TISSUE; HYPERTENSION; INTERNAL MAMMARY ARTERY; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ACETYLCHOLINE; CALCIUM CHANNEL BLOCKERS; ENDOTHELIUM, VASCULAR; HUMANS; MAMMARY ARTERIES; MUSCLE CONTRACTION; MUSCLE RELAXATION; NITROGLYCERIN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0030780889     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199711000-00008     Document Type: Article

References (28)

1. Camereon A, Davis K, Green G, et al. Coronary bypass surgery with internal-thoracic-artery grafts: effects on survival over a 15-year period. N Engl J Med 1996;334:216-9.
2. Grondin CM, Campeau L, Lespérance J, et al. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984;70(Suppl 1):208-12.
3. Lüscher TF, Diederich D, Siebenmann R, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988;319:462-7.
4. Yang Z, Von Segesser L, Bauer E, et al. Different activations of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991;68:52-60.
5. Yang Z, Lüscher TF. Basic cellular mechanisms of coronary graft disease. Eur Heart J 1993;14(Suppl 1):193-7.
6. Nordlander M, Björkman JA, Regårdh CG, et al. Pharmacokinetics and haemodynamic effects of an ultrashort-acting calcium antagonist [abstract]. Br J Anaesth 1996;76(Suppl 2):12.
7. Mueller RL, Scheidt S. Nitroglycerin. In: Messerli FH, eds. Cardiovascular drug therapy. Philadelphia: WB Saunders, 1996; 831-46.
8. Harrison DG, Bates J. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:1461-7.
9. Münzel T, Harrison DG. What causes nitroglycerin tolerance? Clin Cardiol 1994;20:40-7.
10. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992;44:363-76.
11. Nordlander M, Thalèn P. Effects of felodipine on local neurogenic control of vascular resistance. J Cardiovasc Pharmacol 1987;10(Suppl 1):S100-6.
12. Ljung B. Vascular selectivity of felodipine. Drugs 1985;29(Suppl 2):46-58.
13. Singh RN. Atherosclerosis and the internal mammary arteries. Cardiovasc Intervent Radiol 1983;6:72-7.
14. Hills L. Coronary artery bypass surgery: risks and benefits, realistic and unrealistic expectations. J Invest Med 1995;43: 17-27.
15. Yasue H, Matsuyama K, Matsuyama M, et al. Responses of angiographycally normal human coronary arteries to intracoronary injection of acetylcholine by age and segment: possible role of early coronary atherosclerosis. Circulation 1990;81:482-90.
16. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelium dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79: 287-91.
17. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
18. Bossaller B, Habib GB, Yamamato H, et al. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987;79:170-4.
19. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994;89(Suppl 2):87-102.
20. Jett GK, Arcici JM Jr, Hatcher CR, et al. Vasodilatator drug effects on internal mammary artery and saphenous vein grafts. J Am Coll Cardiol 1988;11:1317-24.
21. Huraux C, Makita T, Montes F, et al. What is the best therapy for internal mammary artery vasospasm? [abstract]. Anesthesiology 1995;83:A613.
22. Salmenperä M, Levy JH. The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery. Anesth Analg 1996;82:954-7.
23. He GW, Rosenfeldt FL, Buxton BF, Angus JA. Reactivity of human isolated IMA to constrictor of dilator agents: implications for treatment of IMA spasm. Circulation 1989;78:56-62.
24. 2 levels during cardiopulmonary bypass. Circulation 1980;61:808-14.
25. He GW, Yang CQ, Starr A. Overview of the nature of vasoconstriction in arterial grafts for coronary operations. Ann Thorac Surg 1995;59:676-83.
26. 2: an endothelium-derived vasoconstrictor in human internal mammary arteries. Ann Thorac Surg 1993;56:97-100.
27. He GW, Acuff TE, Ryan WH, et al. Inhibitory effects of calcium antagonists on α-adrenoreceptor-mediated contraction on the human internal mammary artery. Br J Clin Pharmacol 1994;37: 173-9.
28. Liu JJ, Johnston CI, Buxton BF. Synergistic effect of nisoldopine and nitroglycerin on human internal mammary artery. J Pharmacol Exp Ther 1994;268:434-40.